CNS complications of breast cancer - Current and emerging treatment options

被引:22
作者
Kaal, Evert C. A. [1 ]
Vecht, Charles J. [1 ]
机构
[1] Med Ctr Haaglanden, Dept Neurol, NL-2501 CK The Hague, Netherlands
关键词
D O I
10.2165/00023210-200721070-00003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In general, the development of CNS metastases of breast cancer depends on several prognostic factors, including younger age and a negative hormone receptor status. Also, the presence of a breast cancer 1, early onset (BRCA1) germline mutation and expression of the human epidermal growth factor receptor 2 (Her2/ neu) proto-oncogene seem to contribute to an increased rate of development of CNS metastases. The choice of appropriate therapy for brain metastases also depends on prognostic factors, including the age of the patient, the Karnofsky performance score, the number of brain metastases and the presence of systemic disease. Surgery followed by whole brain radiation therapy (WBRT) is generally restricted to ambulant patients with a single brain metastasis without active extracranial disease. In patients who have two to four metastases, stereotactic focal radiotherapy (i.e. radiosurgery) with or without WBRT is usually indicated. In the remainder of patients, WBRT alone provides adequate palliation. Although breast carcinoma is sensitive to chemotherapy, the role of chemotherapy in the treatment of brain metastases is still unclear. Objective responses after cyclophosphamide-based therapies were reported in studies performed in the 1980s. Subgroup analysis of data from a randomised study indicates that survival may improve if WBRT is combined with the radiosensitiser efaproxiral. Interestingly, the Her2/neu antibody trastuzumab, which does not cross the blood-brain barrier, produces systemic responses and enhanced survival, without a clear effect on brain metastases. Breast cancer constitutes the most common solid primary tumour leading to leptomeningeal disease. Clinical symptoms such as cranial nerve dysfunction or a cauda equina syndrome can be treated with local radiotherapy. A randomised study in patients with leptomeningeal disease secondary to breast cancer has revealed that intrathecal chemotherapy is associated with substantially more adverse effects than non-intrathecal treatment, without a clear benefit in terms of response or survival. Intramedullary metastasis is rare but often presents with a rapidly progressive myelopathy. Local radiotherapy may preserve neurological function. Epidural spinal cord metastasis occurs in approximately 4% of patients and can lead to paraplegia. A randomised study has shown that surgical intervention together with local radiotherapy is superior to local radiotherapy alone.
引用
收藏
页码:559 / 579
页数:21
相关论文
共 140 条
[1]   Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer [J].
Abe, K ;
Sasaki, M ;
Kuwabara, Y ;
Koga, H ;
Baba, S ;
Hayashi, K ;
Takahashi, N ;
Honda, H .
ANNALS OF NUCLEAR MEDICINE, 2005, 19 (07) :573-579
[2]   A phase II trial of temozolomide for patients with recurrent or progressive brain metastases [J].
Abrey, LE ;
Olson, JD ;
Raizer, JJ ;
Mack, M ;
Rodavitch, A ;
Boutros, DY ;
Malkin, MG .
JOURNAL OF NEURO-ONCOLOGY, 2001, 53 (03) :259-265
[3]   Spectrum of breast cancer metastasis in BRCA1 mutation carriers:: highly increased incidence of brain metastases [J].
Albiges, L ;
André, F ;
Balleyguier, C ;
Gomez-Abuin, G ;
Chompret, A ;
Delaloge, S .
ANNALS OF ONCOLOGY, 2005, 16 (11) :1846-U3
[4]   Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial [J].
Andrews, DW ;
Scott, CB ;
Sperduto, PW ;
Flanders, AE ;
Gaspar, LE ;
Schell, MC ;
Werner-Wasik, M ;
Demas, W ;
Ryu, J ;
Bahary, JP ;
Souhami, L ;
Rotman, M ;
Mehta, MP ;
Curran, WJ .
LANCET, 2004, 363 (9422) :1665-1672
[5]   Phase II Randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases [J].
Antonadou, D ;
Paraskevaidis, M ;
Sarris, G ;
Coliarakis, N ;
Economou, I ;
Karageorgis, P ;
Throuvalas, N .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3644-3650
[6]   Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system [J].
Barnholtz-Sloan, JS ;
Sloan, AE ;
Davis, FG ;
Vigneau, FD ;
Lai, P ;
Sawaya, RE .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :2865-2872
[7]   Imaging in breast cancer:: Single-photon computed tomography and positron-emission tomography [J].
Bénard, F ;
Turcotte, É .
BREAST CANCER RESEARCH, 2005, 7 (04) :153-162
[8]   Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma [J].
Bendell, JC ;
Domchek, SM ;
Burstein, HJ ;
Harris, L ;
Younger, J ;
Kuter, I ;
Bunnell, C ;
Rue, M ;
Gelman, R ;
Winer, E .
CANCER, 2003, 97 (12) :2972-2977
[9]   BRAIN METASTASES IN BREAST-CANCER - NATURAL-HISTORY, PROGNOSTIC FACTORS AND OUTCOME [J].
BOOGERD, W ;
VOS, VW ;
HART, AAM ;
BARIS, G .
JOURNAL OF NEURO-ONCOLOGY, 1993, 15 (02) :165-174
[10]  
BOOGERD W, 1992, CANCER, V69, P972, DOI 10.1002/1097-0142(19920215)69:4<972::AID-CNCR2820690423>3.0.CO